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INTRODUCTION
Hemorrhagic cystitis is a clinical condition characterized 
by irritating voiding symptoms, urinary frequency, dysuria, 
urgency, strangury, suprapubic discomfort, evident pain, 
microhematuria or even potentially life-threatening hematu-
ria. Hemorrhagic cystitis may result from bacterial and viral 
infections, or develop as a side effect of radio- and chemo-
therapy [18]. Cyclophosphamide – CP (2-[bis(2-chloroethyl)
amino]tetrahydro-2H-1,2,3-oxazaphosphorine 2 oxide) is 
an essential antineoplastic agent which may promote the 
development of hemorrhagic cystitis. This cytostatic agent 
is still used in the treatment of B cell-derived malignancies 
and some solid tumors, as well as in conditioning before 
bone marrow transplantation and in the pharmacotherapy of 
some immune-inflammatory diseases, such as rheumatoid 
arthritis and systemic lupus erythematosus. Cyclophospha-
mide-induced hemorrhagic cystitis (CP-HC), an important 
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adverse reaction to cyclophosphamide, occurs in up to 75% 
of patients receiving high doses of this agent [18]. Despite 
the high incidence of CP-HC, its pathophysiology is still 
unclear. The cascade of events involved in the pathogenesis 
of CP-HC is generally consistent with that observed in the 
case of interstitial cystitis (painful bladder syndrome) [12]. 
However, in contrast to interstitial cystitis, an idiopathic 
disease with an unknown trigger for inflammatory response, 
development of CP-HC is stimulated by toxic 4-hydroxy 
metabolites of cyclophosphamide formed in the liver (and 
perhaps also in the kidneys), especially acrolein. This highly 
reactive and harmful aldehyde accumulates in the bladder 
and may induce urothelial damage due to a direct interaction 
with umbrella cells [18]. Detailed description of consecu-
tive stages of CP-HC pathogenesis, as well as the data on 
the role of immune-inflammatory cells and complex para-
crine and neuroendocrine background of the process, were 
presented elsewhere [1], also in our paper [9]. Arachidonic 
acid derivatives, prostanoids and leukotrienes, are one of the 
most important inflammatory mediators. In recent work, the 
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The complex pathogenesis of cyclophosphamide-induced hemorrhagic cystitis 
involves arachidonic acid-derived inflammatory mediators, among them leukotrienes. 
Montelukast, a leukotriene receptor antagonist, is reported to exert an alleviatory effect 
in the course of cystitis associated with overactive bladder symptoms. The aim of this 
study was to verify whether the effect of montelukast is also associated with its influence 
on autonomic activity. The experiment included 20 rats with cyclophosphamide-induced 
hemorrhagic cystitis (75 mg/kg, four doses every second day), among them, 10 treated 
with oral montelukast (10 mg/kg for 8 days) and 10 controls. Time and frequency domain 
analyses of heart rate variability (HRV) were conducted in all the rats as an indirect measure 
of their autonomic activity. The montelukast-treated animals showed an increase in root 
mean square of successive differences (rMSSD), as well as an increase in HRV spectrum 
total power (TP) and power of very low (VLF) spectral component. This suggests that 
due to its anti-inflammatory and its anti-leukotriene effect, montelukast improves 
overall autonomic activity, with no preferential influence on either the sympathetic or 
parasympathetic part. Furthermore, the increase in VLF corresponds to attenuation of 
inflammatory response. In conclusion, this study showed that aside from its antagonistic 
effect on leukotriene receptors, montelukast can also modulate autonomic activity.
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role of prostanoids in urinary bladder function under normal 
and pathological conditions is increasingly discussed. Both 
1 and 2 cyclooxygenase isoforms are found in the bladder, 
and prostaglandins are generally postulated to contribute to 
bladder overactivity. Consequently, prostaglandin-targeting 
agents are increasingly postulated as a novel pharmacologi-
cal approach to bladder dysfunction [24]. In contrast, little is 
known about the role of leukotrienes in CP-HC pathogenesis. 
Leukotrienes (LT), released to the bladder wall from mast 
cells, along with other granule-stored preformed mediators 
(e.g. heparin, histamine), are newly synthesized potent lipid 
inflammatory mediators. LT were shown to be among the 
most potent chemotactic agents, and are factors contributing 
to increased permeability and vasoactive reactions. Several 
chronic inflammatory conditions, such as dermatitis, arthritis 
and unspecific inflammatory bowel diseases (all predomi-
nantly associated with LT class B4), asthma, allergic rhinitis 
and nephritis (mainly associated with LT class C4) have 
been linked to LT overproduction [13]. Bouchelouche et al. 
demonstrated an increase in the urinary excretion of LT 
class E4 in patients with interstitial cystitis [3]. The same 
authors found leukotriene receptors in bladder tissues [4], 
and hypothesized that anti-leukotriene agents may constitute 
a novel treatment for cystitis. This hypothesis was confirmed 
empirically [5], as 10 women diagnosed with interstitial 
cystitis showed a significant decrease in 24-hour urinary 
frequency, nocturia and pain after a 1-month treatment 
with the leukotriene receptor antagonist, montelukast; these 
beneficial effects persisted for the 3 months of the treat-
ment. The efficacy of montelukast (MLKT) in the control 
of bladder overactivity was also reported by Traut et al. 
[27], who demonstrated that administration of this agent to 
a patient with interstitial cystitis and concomitant allergic 
rhinitis resulted in substantial attenuation of urinary urgency 
and pain; however, the effect was no longer observed after 
discontinuation of MLKT treatment. Altogether, these data 
point to anti-leukotriene treatment as an interesting phar-
macological approach to cystitis.
Taking into account the premises mentioned above, we 
decided to clarify whether the beneficial anti-leukotriene 
effect of montelukast observed in patients with bladder over-
activity is also associated with its influence on the autonomic 
nervous system (ANS) activity. Therefore, the aim of this 
study was to analyze autonomic activity, determined on the 
basis of heart rate variability (HRV), in montelukast-treated 
rats with cyclophosphamide-induced hemorrhagic cystitis.
MATERIALS AND METHODS
All the hereby presented experiments were performed 
in line with the National Institute of Health Guidelines for 
the care and use of laboratory animals, and the European 
Council Directive of 22 September 2010 for Care and Use 
of Laboratory Animals (2010/63/UE). The protocol of the 
study was approved by the First Local Ethics Committee 
in Krakow. 
The experiment included 20 eight-week-old albino Wistar 
rats with mean initial body weight of 198.4 ± 7.9 g, obtained 
from the central animal house at the Faculty of Pharmacy 
UJCM. Upon admission to the local animal house at the 
Department of Pathophysiology, the animals acclimated to 
new living conditions for one week. During this period, the 
rats were housed under standard conditions, five individuals 
per cage, with unlimited access to water and food (Labofeed, 
Kcynia). The first stage of the proper experiment comprised 
the measurement of daily water and food intake, determined 
with an aid of individual metabolic cages. The following 
day, the rats were randomized to either the control group 
(group 1, n=10) or to the group treated with the oral leukot-
riene receptor antagonist, montelukast (group 2, n = 10). On 
the 1st, 3rd, 5th and 7th day of the experiment, body weight of 
the rats was determined and then each animal received an 
intraperitoneal injection of cyclophosphamide (75 mg/kg). 
This dosage regimen, subject to minor modifications, has 
been used to induce chronic CP-HC in many previous 
studies [6,10]. Moreover, animals from group 2 received 
MLKT dissolved in an individually predetermined daily 
volume of water. A commercially available preparation 
containing MLKT was used (Montelukast Sandoz, 500-mg 
sachets containing 4 mg of active substance). MLKT was 
administered at 2 mg per rat per day. Effective doses of 
MLKT were calculated, adjusted for potential changes in 
body weight, and, additionally, corrected for daily intake 
of water the case of montelukast (after 1st CP dose – 9.91 
mg/kg, after 2nd CP dose – 10.32 mg/kg, after 3rd CP dose – 
10.66 mg/kg and after 4th CP dose – 11.05 mg/kg). MLKT 
was continued for 7 days, i.e. till the end of CP treatment. 
The mean cumulative dose of MLKT administered through-
out the 7-day treatment period was 10.49 mg/kg, which was 
consistent with the cumulative dose of MLKT used by other 
authors (10 mg/kg orally) [19].
Both control and MLKT-treated rats were kept in individ-
ual cages, with limited access to water and unlimited access 
to food. All animals survived till the end of the treatment, 
but their condition deteriorated gradually with subsequent 
CP doses. On the 7th day of the experiment, after receiving 
the last dose of CP, all animals were placed back in single 
metabolic cages with still maintained, predetermined access 
to water (with dissolved MLKT in the case of group 2) to 
estimate their food intake, final body weight and 24-hour 
urine output.
On the 8th day, 20-minute resting ECG recordings were 
obtained from all animals under general pentobarbital 
anesthesia (Morbital, 60 mg pentobarbital sodium per kg 
body weight), and subjected to time and frequency domain 
analyses of heart rate variability (HRV).
The ECG signal used for HRV analysis was collected 
utilizing Ag/AgCl pediatric electrodes (EK-S30 Sorimex 
PSG) and Polygram System (ADInstruments) hardware and 
software, following hair removal, application of abrasion 
paste and standard ECG gel.
HRV is an analysis of normal-normal heart beat intervals 
in sinus rhythm, as they are known to be modulated by the 
ANS [15,22,25]. The following parameters were calculated 
on the basis of the obtained ECG recordings: 
1) standard time parameters: mean, max and min NN inter-
vals, standard deviation of all NN intervals (SDNN), root 
mean square of successive differences (rMSSD) (all in 
ms), mean heart rate (HR, 1/min), and 
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2) spectral (frequency) parameters: total HRV spectrum 
power (TP), power of very low frequency component 
(VLF), power of low frequency component (LF) and 
power of high frequency component (HF) (all in ms2). 
Moreover, we normalized the HRV spectrum for VLF so 
as to obtain two normalized parameters, nLF and nHF, 
both expressed in normalized units (n.u.) [15,22,25].
Similar to previous studies (e.g. Goncalves et al. [11]: 
0.10 < LF < 1.0 <HF < 3.0), the spectrum bands for respec-
tive components were set at 0.18 < VLF < 0.28 < LF < 0.78 
< HF <3. 
Once HRV recordings had been taken, a lethal dose of 
sodium pentobarbital was administered to each animal (160 
mg pentobarbital sodium per rat), and urinary bladders were 
collected to determine their absolute wet weight (BWW) 
and its proportion in final body weight. The bladders 
were removed along with the proximal urethra, carefully 
emptied and immediately thereafter weighted on an ana-
lytical scale. According to literature, the severity of cystitis 
may be evaluated not only on the basis of macroscopic 
and microscopic changes in the urinary bladder, but also 
on the basis of BWW. Therefore, BWW is considered to 
be an indirect marker of cystitis and bladder dysfunction 
[28]. After determining BWW, the bladders were fixed in 
4% formalin + PBS solution and sent for histopathological 
examination. Routinely prepared microscopic slides stained 
with hematoxylin and eosin were examined for the severity 
of inflammatory lesions.
The significance of intergroup differences related to body 
weight, bladder wet weight, average daily water intake and 
daily urine excretion was verified with parametric Student 
t-test – with the threshold of significance set at p=0.05. 
The calculated HRV results were submitted to two-stage 
statistical analysis. In the first step, the non-parametric 
Mann-Whitney test was performed with the calculation of 
both tested statistics (U and Z values). As none of the HRV 
parameters were distributed normally, they were subjected 
to logarithmic transformation prior to the next step of the 
statistical analysis based on the t-Student test. We adopted 
final statistical significance if both tests demonstrated p 
<0.05 for the estimated parameter.
RESULTS
Both groups of rats showed progressive weight loss after 
administration of successive CP doses. Indeed, significant 
intergroup difference in body weight was observed solely 
after administration of the 1st CP dose. Considering intra-
group body weight changes, we found that the starting and 
final differences were statistically significant (p<0.05) in 
both groups. 
However, the two groups did not differ significantly 
in terms of their BWW and final 24-hour urine outputs, 
although slightly lower values of the latter parameter were 
observed in the case of MLKT-treated rats.
Detailed characteristics of rats from the two groups are 
given in Table 1. All results are presented as mean values 
± SD. 
Table 1. The characteristics of the studied animals – CP-HC model. 
Statistical analysis was performed for intergroup differences
Group 1
control CP-HC 
rats
Group 2
CP-HC rats 
+ MLKT
Statistic
Group 
1-2
starting body weight [g] 198.4±7.9 
body weight after CP 1st dose [g] 188.0±11.3 201.9±12.3 p=0.03
body weight after CP 2nd dose [g] 184.5±9.1 193.9±11.3 NS
body weight after CP 3rd dose [g] 183.7±10.5 188.8±10.0 NS
body weight after CP 4th dose [g] 180.0±11.4* 181.0±14.1* NS
average daily water intake [ml] 22.0±2.3 25.1±4.1 NS
bladder wet weight [mg] 131.7±25.6 121.5±24.3 NS
bladder wet weight related to final 
body weight [%] 0.073±0.01 0.067±0.01 NS
24-hour urine excretion day after 
4th CP dose [ml] 14.8±6.4 10.3±5.9 NS
Footnotes: CP-HC – cyclophosphamide-induced hemorrhagic cystitis, 
CP – cyclophosphamide, MLKT – montelukast, NS – non significant,  
* – intragroup (1-1; 2-2) statistically significant difference (p < 0.05) – 
considering the starting and final values
HRV analysis
The two groups did not differ significantly in terms of 
their parameters determined on time domain HRV analysis, 
although rMSSD reached a statistically insignificant higher 
value in MLKT-treated rats than in the controls. 
Spectral domain HRV analysis revealed intergroup differ-
ences in the HRV spectrum, yet only the TP and VLF results 
met the assumption of statistical significance. In other cases, 
we have shown a partial statistical significance (in the Mann-
Whitney test), but which was unconfirmed in the t-Student 
test. Both total power (TP) and power of very low (VLF) 
spectral component were higher in the MLKT-treated rats. 
The values of remaining non-normalized spectral domain 
parameters did not differ significantly between the groups, 
although both LF and HF were slightly higher in MLKT-
treated animals. What is more, the values of both normal-
ized parameters, nLF and nHF, did not differ significantly 
between the groups, despite an insignificant tendency to 
higher nLF and lower nHF in MLKT-treated rats.
The statistical estimation is presented in Table 2 and the 
detailed results of time and spectral domain HRV analyses 
are revealed in Table 3. All results are presented as mean 
values ± SD. 
Table 2. The results of the statistical estimation
HRV parameter
Mann-Whitney test
t-Student test
U statistic Z statistic
Time-domain parameters
mean NN p<0.05 NS NS
max NN NS NS NS
min NN NS NS NS
range p<0.05 NS NS
average HR p<0.05 p<0.05 NS
SDNN NS NS NS
rMSSD p<0.05 NS NS
Spectral-domain parameters
TP p<0.05 p<0.05 p<0.05
VLF p<0.05 p<0.05 p<0.05
LF NS NS NS
HF NS NS NS
nLF p<0.05 p<0.05 NS
nHF p<0.05 p<0.05 NS
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Table 3. Time- and spectral-domain HRV analysis parameters 
obtained from 20-minute ECG recordings in rats – CP-HC model
CP-HC rats 
control
CP-HC rats
treated  
with MLKT
Final  
statistic 
estimation
TIME-DOMAIN HRV ANALYSIS
mean NN [ms] 158.81±11.66 167.64±13.27 NS
max NN [ms] 189.91±2.52 188.79±3.52 NS
min NN [ms] 144.19±6.44 143.02±5.59 NS
range [ms] 42.74±8.25 45.74±5.43 NS
average HR [bpm] 380.15±26.93 359.87±26.68 NS
SDNN [ms] 7.44±1.99 10.07±4.29 NS
rMSSD [ms] 6.27±4.07 15.82±11.16 NS
SPECTRAL-DOMAIN HRV ANALYSIS
TP [ms2] 17.39±15.55 45.23±37.10 p=0.05
VLF [ms2] 11.26±9.57 36.20±31.18 p=0.05
LF [ms2] 2.79±2.31 4.35±3.59 NS
HF [ms2] 4.49±3.97 6.14±5.37 NS
nLF [n.u.] 39.54±14.23 50.06±15.51 NS
nHF [n.u.] 60.40±14.23 49.94±15.51 NS
Footnotes: CP-HC – cyclophosphamide-induced hemorrhagic cystitis, 
MLKT – montelukast, HRV – heart rate variability, mean NN – mean 
normal-normal interval [ms], max NN – maximal normal-normal interval 
[ms], min NN – minimal normal-normal interval [ms], range – mean differ-
ence between max and min intervals [ms], average HR – average heart rate 
[bpm – 1/min], SDNN – total standard deviation of all normal-normal inter-
vals [ms], rMSSD – root mean square of successive differences, TP – total 
power of HRV spectrum, VLF – power of very low frequency component 
in the HRV spectrum, LF – power of low frequency component in the HRV 
spectrum, HF – power of high frequency component in the HRV spectrum, 
nLF – normalized LF, nHF – normalized HF, NS – non-significant
Histopathological analysis
The specimens from the bladders of control rats with 
experimentally induced CP-HC showed the presence 
of chronic, partially purulent, inflammatory infiltrate. 
Moreover, the bladder wall was edematous and hyperemic, 
with small amount of non-specific granulomatous tissue.
Only two specimens from the bladders of MLKT-treated 
rats showed a mild degree edema, and a trace of chronic 
inflammatory infiltrate was found in only one specimen. The 
remaining bladder specimens from MLKT-treated animals 
did not show any abnormalities upon histopathological 
evaluation.
DISCUSSION
The development of the CP-HC model is related to the 
adverse, systemic CP action, including body weight loss. 
The reason of the progressive body weight reduction was 
repetitive CP dosage regimen and cumulative, cytotoxic CP 
effect due to its action affecting not only proliferating can-
cerous cells, but also healthy ones undergoing rapid division 
(e.g. gastrointestinal epithelial cells). The CP -evoked muco-
sitis of the alimentary tract with possible ulceration leads 
to impaired nutrient absorption and finally results in mal-
nutrition [21]. Moreover, CP was also reported to cause 
taste alternation (reduced taste sensitivity – hypogeusia, or 
even complete loss of taste – ageusia) and it can also lead 
to reduced food intake [20]. Indeed, considering all of the 
study animals together, we showed a diminished daily food 
consumption at the end of the experiment (20.8 ± 3.9 g), 
compared to the initial value assessed in the beginning (59.3 
± 8.3 g; p<0.05). Furthermore, we found some significant 
changes in the HRV spectra of rats with cyclophospha-
mide-induced hemorrhagic cystitis that had been treated 
with montelukast (a leukotriene receptor antagonist). This 
was, namely, an increase in total spectrum power (TP) and 
power of very low (VLF) spectral component. Moreover, 
histopathological abnormalities found in the specimens from 
MLKT-treated rats were markedly less evident than in the 
controls.
TP is generally considered a marker of global autonomic 
tone and excitability. The physiological meaning of the 
VLF effect, however, still remains unclear, although this 
parameter accounts for about 90% of the HRV spectrum 
[22]. The origin of VLF is complex; this parameter is pos-
tulated to be a marker of various circadian and neuroendo-
crine rhythms, thermoregulatory processes, renin-angio-
tensin system activity and hemodynamic feedback delays. 
Although VLF cannot be unambiguously linked to any of 
the two ANS arms, as a major marker of physical activity 
and general stress, it is considered to be a measure of sympa-
thetic, rather than parasympathetic tone [15,25]. According 
to some authors, VLF reflects severity of inflammation, and 
it negatively correlates with the level of pro-inflammatory 
cytokines [14,23]. In addition, some researchers have found 
significant inverse correlations between inflammatory bio-
markers, e.g. C-reactive protein (CRP), and selected HRV 
metrics derived from both time and frequency domains, 
especially SDNN and VLF [16,17].
In our previous studies, we have assessed the autonomic 
nervous system activity in rats with a “pure” model of 
CP-HC, also using HRV methodology. Therein, we revealed 
that CP-HC rats were characterized by a statistically signifi-
cant decrease of HRV total power and power of all the non-
normalized, basic components: VLF, LF and HF, compared 
to intact animals. In such work, we concluded that cyclo-
phosphamide reduced global autonomic activity and the 
diminished VLF power, together, might be considered as 
an indirect HRV marker of systemic inflammation evoked 
by CP [7,8].
The spectral HRV analysis of the CP-HC animals treated 
with montelukast, performed in the present experiment, 
showed opposite results – a significant increase of VLF 
and TP was demonstrated. In our opinion, therefore, the 
applied MLKT dose was sufficient to exert a modulatory 
effect on the autonomic activity (which was confirmed by 
the VLF and TP changes in HRV spectrum), but not suf-
ficient to alleviate the adverse CP systemic effects which 
contributed to body weight loss and general deterioration 
of the study animals. 
In line with widely accepted international HRV interpreta-
tion guidelines [22], the increase in VLF of MLKT-treated 
rats might result from the anti-inflammatory effect of this 
agent, specifically, the blockage of leukotriene receptors 
and the functional inhibition of these pro-inflammatory lipid 
mediators. This, in turn, led to improvement of global auto-
nomic activity, as shown by increased TP. 
There is a link between inflammatory mediators and auto-
nomic activity. Chemical mediators are equally effectors 
of inflammation and signal molecules for both autonomic 
and somatic afferent fibers. The neural immunomodulation 
pathway is potentiated through the direct, humoral action of 
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circulating proinflammatory cytokines, reaching the central 
neuronal structures. [2]. Conversely, within the autonomic 
nervous system, through the release from efferent terminals, 
the main neurotransmitters, together with a variety of co-
transmitters, acting via receptors present on the surface of 
immune cells, can also affect the function of the immuno-
competent cells. Thus, there is a strong, neuroimmunological 
interdependence [2]. 
Montelukast has been reported to exert additional, anti-
inflammatory properties. These include 5-lipooxygenase 
inhibition, antagonizing the effects of agents acting via 
purinergic P2Y receptors, inhibition of pro-inflammatory 
cells adhesion and migration [26]. MLKT has also an ability 
to diminish pro-inflammatory mediators and that action 
indirectly contributes to the modulation of the autonomic 
activity. This effect results from MLKT-evoked cAMP 
elevation due to the adenosine 3,5-cyclic monophosphate 
phosphodiesterase (PDE) inhibition [26]. Elevated cyto-
solic Ca level is a necessary condition for neutrophil stored 
mediators degranulation and for the production of lipid 
mediators. Cyclic AMP promotes a restoration of calcium 
cellular homeostasis in neutrophils and other cells, thus 
cAMP-elevating agents such as montelukast may provide 
an additional, indirect anti-inflammatory effect due to the 
decrease of some cellular mediators release [26]. 
Our findings suggest that montelukast, apart from the 
aforementioned VLF effect, may also change some remain-
ing HRV parameters. However, owing to the ambiguous 
profile of changes in rMSSD, LF, HF, nLF and nHF of 
MLKT-treated rats, we were unable to conclude if this 
agent induces any shift in the sympathetic/parasympa-
thetic balance. According to HRV interpretation standards 
[22], rMSSD and HF are pure markers of parasympathetic 
activity. In turn, LF is influenced by both sympathetic and 
parasympathetic tone, although the effect of the former is 
somehow stronger. Therefore, HRV spectra are usually 
normalized to obtain nLF and nHF values, being, respec-
tively, pure markers of sympathetic and parasympathetic 
activity [15,22,25]. Although our MLKT-treated rats showed 
a trend of increasing rMSSD, this was not associated with 
concomitant changes in non-normalized and normalized 
spectral parameters, HF and nHF. However, we also did 
not find a significant intergroup difference in sympathetic 
activity measure, nLF. Altogether, these findings suggest 
that MLKT does not cause a shift in the sympathetic/para-
sympathetic balance. Yet, the fact that MLKT-treated rats 
showed a tendency to higher LF and HF, and demonstrated 
slightly lower nLF and nHF values than the controls, justi-
fies further research on the influence of montelukast on the 
sympathetic/parasympathetic balance. At present, we can 
only state that this agent enhances global autonomic activity, 
and an increase in the VLF power of the HRV spectrum may 
reflect lower severity of inflammation. 
CONCLUSIONS
MLKT treatment resulted in an improvement of the his-
tological abnormalities revealed in the bladder assessment 
of the CP-HC animals. 
Montelukast seems to exert an anti-inflammatory effect 
during the course of CP-HC. This was not only due to leu-
kotriene receptor antagonism, but also due to indirect stimu-
lation of autonomic activity. 
An increase in VLF power of the HRV spectrum observed 
after administration of montelukast may be considered 
additional, indirect evidence for the anti-leukotriene and 
anti-inflammatory effect of this agent.
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